# US 2024/0197702 A1 · Antiseptic-antibiotic gumbos effective against gram-negative pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197702 A1
- Document ID: US20240197702A1
- Status: Published application
- Kind: A1
- Application number: 17/909,869
- Filed: 2021-03-10
- Published: 2024-06-20
- Earliest claimed: 2020-03-10
- Assignees: Board of Supervisors of Lousiana State University and Agricultural and Mechanical College
- Applicants: Board of Supervisors of Lousiana State University and Agricultural and Mechanical College
- Inventors: Isiah Manuel WARNER; Jeffrey Andre HOBDEN; Kelsey Marie LOPEZ
- Web page: https://patentgrep.com/patent/US20240197702A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Ion-pairs known as GUMBOS (group of uniform materials based on organic salts) from antiseptics (chlorhexidine and octenidine) and the beta-lactam antibiotic, ceftriaxone. The antimicrobial efficacy of these GUMBOS and unreacted stoichiometric equivalent mixtures were compared to ceftriaxone and azithromycin alone. On a molar basis, GUMBOS were equivalent to ceftriaxone and 10× more effective in killing N. gonorrhoeae than azithromycin. They were more than 100× more effective than either antibiotic in killing CRE. A strategy involving the electrostatic interaction between a common antiseptic and a discontinued antibiotic (octenidine and carbenicillin) was also evaluated as a treatment for gonorrhoea. Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A composition comprising an antiseptic in ionic association with an antibiotic as an ion-pair solid-phase organic salt, wherein the antiseptic and the antibiotic synergistically interact whereby the composition has a Minimal Inhibitory Concentration (MIC) against a sensitive bacterial species that is less than the sum of the MICs of the antiseptic and the antibiotic individually.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the antiseptic is effective in modulating the proliferation or viability of a gram-negative strain of a bacterial species when in contact with said strain.

### Claim 37 (depends on 35)

The composition of claim 35, wherein the antibiotic is effective in modulating the proliferation or viability of a carbapenem-resistant bacterial strain.

### Claim 38 (depends on 35)

The composition of claim 35, wherein the antiseptic is chlorhexidine or octenidine.

### Claim 39 (depends on 35)

The composition of claim 35, wherein the antibiotic is a □-lactam.

### Claim 40 (depends on 35)

The composition of claim 35, wherein the composition comprises octenidine and ceftriaxone, chlorhexidine and ceftriaxone, or octenidine and carbenicillin.

### Claim 41 (depends on 35)

The composition of claim 35, wherein the composition further comprises a pharmaceutical carrier.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the composition is formulated for delivery to a subject human or animal intravascularly, or directly to a tissue of the subject.

### Claim 43

A method of generating a group of uniform materials based on organic salts (GUMBOs) comprising mixing a salt of an antibiotic and a salt of either chlorhexidine or octenidine in water for an extended period, thereby generating an antiseptic-antibiotic ion-pair solid-phase organic salt.

### Claim 44 (depends on 43)

The method of claim 43, wherein the chlorhexidine salt is chlorhexidine diacetate salt.

### Claim 45 (depends on 43)

The method of claim 43, wherein the antibiotic is a □-lactam.

### Claim 46

A method of reducing the proliferation or viability of a bacterial strain comprising contacting a population of the bacterial strain or strains with an antiseptic-antibiotic ion-pair solid-phase organic salt.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antiseptic is effective in modulating the proliferation or viability of a strain of Neisseria gonorrhoeae or a carbapenem-resistant Enterobacteriaceae.

### Claim 48 (depends on 46)

The method of claim 46, wherein the composition comprises at least one of octenidine and ceftriaxone, chlorhexidine and ceftriaxone, and octenidine and carbenicillin.